Horsham, PA | March 31, 2026 — Kyfora Bio today announced the launch of SmashGene™, a next‑generation transfection reagent engineered to deliver higher titers on its own compared to leading competitor reagents that require enhancers. Designed to simplify workflows while maximizing performance, SmashGene™ enables process developers to achieve more with less complexity, fewer components, and lower overall cost.
As cell and gene therapies experience unprecedented growth, manufacturers face increasing pressure to simplify processes, improve reproducibility, and control cost per dose. Conventional transfection workflows that depend on multiple components and enhancers introduce inconsistency, increase operational burden, and add downstream demands—ultimately slowing timelines and increasing production expense. SmashGene™ addresses these challenges by delivering high yields without the need for enhancers, through a streamlined approach that reduces inputs, improves consistency, and accelerates execution from flask to bioreactor.
“SmashGene™ is redefining what efficient transfection should look like,” said Leena Mol Thuruthippallil, PhD, CCO of Kyfora Bio. “By removing the need for enhancers/multi-component transfection systems, we’re eliminating unnecessary complexity from bioprocess workflows—enabling higher productivity, lower cost of goods, and a faster, more scalable path to clinical and commercial manufacturing.”
Built on Kyfora Bio’s deep in-house expertise in synthetic chemistry and transfection, SmashGene™ performs reliably across adherent and suspension cultures and a wide range of media conditions, supporting diverse upstream process strategies. Its fully synthetic formulation, manufactured in-house in the United States, ensures consistent quality, dependable supply, and complete process control. The result is a transfection solution designed for modern cell and gene therapy development, combining simplicity, scalability, and strong performance while helping organizations reduce bioreactor runs and lower cost per dose.
Kyfora Bio delivers high-performance transfection reagents, excipients, and next-gen solutions that empower the development of cutting-edge cell and gene therapies. As a subsidiary of Polysciences—an industry leader with over 60 years of chemical manufacturing expertise—Kyfora leverages scientific innovation to revolutionize the future of advanced therapies, from discovery to delivery.
